NZ747468A - Nicotine particle delivery consumable - Google Patents
Nicotine particle delivery consumableInfo
- Publication number
- NZ747468A NZ747468A NZ747468A NZ74746817A NZ747468A NZ 747468 A NZ747468 A NZ 747468A NZ 747468 A NZ747468 A NZ 747468A NZ 74746817 A NZ74746817 A NZ 74746817A NZ 747468 A NZ747468 A NZ 747468A
- Authority
- NZ
- New Zealand
- Prior art keywords
- receptacle
- nicotine
- cavity
- capsule
- particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 126
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 106
- 229960002715 Nicotine Drugs 0.000 title claims abstract description 100
- 229930015196 nicotine Natural products 0.000 title claims abstract description 100
- 239000002775 capsule Substances 0.000 claims abstract description 58
- 239000012528 membrane Substances 0.000 claims abstract description 22
- 238000007789 sealing Methods 0.000 claims abstract description 4
- 210000004072 Lung Anatomy 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000011888 foil Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 description 75
- 235000019634 flavors Nutrition 0.000 description 59
- 239000000843 powder Substances 0.000 description 33
- 239000000203 mixture Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000391 smoking Effects 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 238000005054 agglomeration Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- MMOPGICOOYBFJU-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.CN1CCCC1C1=CC=CN=C1 MMOPGICOOYBFJU-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- 235000019454 L-leucine Nutrition 0.000 description 3
- 239000004395 L-leucine Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- FFYVQVZXWDGRAY-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrate Chemical compound O.CN1CCCC1C1=CC=CN=C1 FFYVQVZXWDGRAY-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N Anethole Natural products COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- POIARNZEYGURDG-FNORWQNLSA-N Damascenone Chemical compound C\C=C\C(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-FNORWQNLSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N Guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 235000016247 Mentha requienii Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 240000008962 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- WTOYNNBCKUYIKC-JMSVASOKSA-N Nootkatone Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CC(=O)C=C21 WTOYNNBCKUYIKC-JMSVASOKSA-N 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N Phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 240000000280 Theobroma cacao Species 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 235000006682 bigleaf mint Nutrition 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008369 fruit flavor Substances 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000006679 mint Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 229930007850 β-damascenone Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GKTOAHZEMRRUKF-HVDRVSQOSA-N (2S)-2-aminopentanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)[C@@H](N)CCC(O)=O.CN1CCCC1C1=CC=CN=C1 GKTOAHZEMRRUKF-HVDRVSQOSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001730 (5R)-5-butyloxolan-2-one Substances 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- SKZDZXPBBYUFBY-WLHGVMLRSA-N (E)-but-2-enedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCCC1C1=CC=CN=C1 SKZDZXPBBYUFBY-WLHGVMLRSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N 2-Heptanone Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- JZBCTZLGKSYRSF-UHFFFAOYSA-N 2-ethyl-3,5-dimethylpyrazine Chemical compound CCC1=NC=C(C)N=C1C JZBCTZLGKSYRSF-UHFFFAOYSA-N 0.000 description 1
- 239000001363 2-ethyl-3,5-dimethylpyrazine Substances 0.000 description 1
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2S)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 description 1
- VWTHFJXLFGINSW-UHFFFAOYSA-N 2-hydroxypropanoic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 VWTHFJXLFGINSW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- IPBFYZQJXZJBFQ-UHFFFAOYSA-N 5-butyloxolan-2-one Chemical compound CCCCC1CCC(=O)O1 IPBFYZQJXZJBFQ-UHFFFAOYSA-N 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CBOQJANXLMLOSS-UHFFFAOYSA-N Ethylvanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 235000010705 Eucalyptus maculata Nutrition 0.000 description 1
- 235000009683 Eucalyptus polybractea Nutrition 0.000 description 1
- 235000009687 Eucalyptus sargentii Nutrition 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- INAXVXBDKKUCGI-UHFFFAOYSA-N Furaneol Chemical compound CC1OC(C)=C(O)C1=O INAXVXBDKKUCGI-UHFFFAOYSA-N 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229960001867 Guaiacol Drugs 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229940010454 Licorice Drugs 0.000 description 1
- XPCTZQVDEJYUGT-UHFFFAOYSA-N Maltol Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 1
- YKVWPZJHENXDAJ-VOTSOKGWSA-N Megastigmatrienone Chemical compound CC1=CC(=O)CC(C)(C)C1\C=C\C=C YKVWPZJHENXDAJ-VOTSOKGWSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 229940069688 Nicotine Bitartrate Drugs 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N Pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PQDRXUSSKFWCFA-CFNZNRNTSA-N Solanone Chemical compound CC(=O)CC[C@@H](C(C)C)\C=C\C(C)=C PQDRXUSSKFWCFA-CFNZNRNTSA-N 0.000 description 1
- 240000005147 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 240000007329 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 230000000881 depressing Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 235000001612 eucalyptus Nutrition 0.000 description 1
- 235000001617 eucalyptus Nutrition 0.000 description 1
- 235000001621 eucalyptus Nutrition 0.000 description 1
- 235000006356 eucalyptus Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- -1 lactose or mannitol Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000014063 licorice root Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 235000005227 red mallee Nutrition 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 229930004725 sesquiterpenes Natural products 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Abstract
nicotine particle delivery consumable article includes a receptacle having a body extending from a receptacle first end to an opposing receptacle second end and defining a cavity. A capsule is disposed within the cavity. The capsule contains particles including nicotine. The receptacle includes a membrane sealing the receptacle first end and an air outlet extending through the receptacle second end and into the cavity. An air inlet, close to the receptacle first end, extends through a side wall of the body and into the cavity. membrane sealing the receptacle first end and an air outlet extending through the receptacle second end and into the cavity. An air inlet, close to the receptacle first end, extends through a side wall of the body and into the cavity.
Description
PCT/18201 46
NICOTINE PARTICLE DELIVERY CONSUMABLE
This disclosure relates to an article that includes a receptacle containing a capsule
containing nicotine particles. The e may rotate about a longitudinal axis when air flows
through the receptacle.
Nicotine particle inhalers are not always suitable to provide nicotine particles to the lungs
at inhalation or air flow rates that are within conventional g regime inhalation or air flow
rates. Nicotine particle inhalers do not always include nicotine particle consumable which is
easily replaceable once consumed.
It is desirable to provide an article that contains a capsule holding nicotine particles that
may be a modular component of an inhaler and be easily replaceable once consumed. It is
desirable that the e facilitates ry of nicotine particles to the consumer at tional
smoking regime inhalation or air flow rates. The consumable article may alleviate one or more
of the above mentioned problems.
This disclosure is directed to an e comprising a receptacle and a capsule disposed
in a cavity of the receptacle. The e contains particles comprising nicotine. The receptacle
includes a body extending from a receptacle first end to an opposing receptacle second end
and defining a cavity. A membrane seals the acle first end. An air outlet extends through
the receptacle second end into the . An air inlet extends through a side wall of the body
and into the cavity. The air inlet is closer to the receptacle first end than the acle second
end.
Airflow management through the receptacle preferably causes the capsule to rotate and
release nicotine particles (once pierced) into the airflow. The receptacle may be sealed or air-
tight prior to ption or insertion into an inhaler device.
Preferably, the article is suitable to be used in a nicotine particle r. The article may
be a modular component of a multi-use nicotine particle inhaler. The article may be easily
replaceable within the multi-use inhaler. Once consumed, the article may be removed from the
PCT/18201 7/053546
multi-use inhaler and ded. The acle may be sealed prior to ion into the inhaler
to preserve the e within the receptacle.
Advantageously, the article described herein provides a r component approach
when ed with a re-usable or multi-use inhaler. The article may be sealed or air-tight prior
to consumption or insertion into an inhaler device. Airflow management through the receptacle
may cause the capsule to rotate during inhalation and ption. This rotation may suspend
and aerosolize the nicotine particles in the inhalation air moving through the article. The capsule
may also comprise flavour particles. These flavour particles may be larger than the nicotine
particles and assist in transporting the nicotine particles into the lungs of the user while the
flavour particles preferentially remain in the mouth or buccal cavity of the user.
The term “nicotine" refers to nicotine and nicotine derivatives such as ase nicotine,
nicotine salts and the like.
The term “‘flavourant” or “flavour" refers to leptic compounds. compositions, or
materials that alter and are intended to alter the taste or aroma characteristics of ne during
consumption or inhalation thereof. The term “flavourant” or “flavour” preferably refers to
compounds disclosed in the Flavor & Extract Manufacturers Association (FEMA) Flavor
Ingredient Library and in particular in the GRAS Flavoring Substances publications 3 to 27, for
example. see Hall, R.L. & Oser, B.L., Food Technology, ry 1965 pg 151-197, and in the
GRAS flavoring substances 27 SM. Cohen et al.. Food Technology Aug. 2015 pg. 40-59, and
intervening GRAS Flavoring Substances publications 4 to 26. For the purpose of this disclosure,
nicotine is not considered as a flavourant or flavour.
The size of a le, stated herein, preferably refers to the aerodynamic diameter of the
particle. The aerodynamic diameter of the particles is preferably measured with a cascade
impactor.
The nicotine particle delivery consumable or article described herein may be combined
with an inhaler or dry powder r to deliver the nicotine particles to a consumer. A plurality
of these articles may be combined with an inhaler to form a kit. The nicotine particles may be
PCT/18201 46
red with the inhaler at inhalation or air flow rates that are within conventional smoking
regime inhalation or airflow rates.
An inhaler article may include an inhaler body extending between a mouthpiece portion
and a distal end portion. An inhaler receptacle cavity may be defined within the inhaler body
between the mouthpiece portion and the distal end portion. The article (nicotine particle delivery
consumable) may define an outer surface that mates with the inhaler receptacle cavity. A
consumer may access the inhaler receptacle cavity to insert the article into the inhaler
receptacle cavity or replace a depleted article (nicotine particles delivered to the consumer) with
a full or un-used e into the inhaler receptacle cavity.
1O An air inlet may extend through a side wall of the inhaler body and into the inhaler
receptacle cavity. A mouthpiece air channel is fluidly connected to the inhaler receptacle cavity
and a proximal end of the mouthpiece. The air inlet or air inlets that extend h the inhaler
body may mate or align with the air inlet or air inlets that extend through the sidewall of the
article placed into the inhaler acle cavity. The article air outlet extending thought the
receptacle second end may mate or align with the iece air channel of the inhaler body.
Once the article is placed into the inhaler receptacle cavity. air may flow through the article from
the air inlet through the cavity and through the air outlet onto the mouthpiece air l.
The inhaler body may resemble a smoking article or cigarette in size and shape.
The article includes a receptacle defining a cavity. A capsule is ed within the
cavity. The receptacle is configured to n the capsule within the cavity. The cavity may
have a ar cross-section extending along at least a portion of the cavity length. The cavity
may have a central axis or centroid longitudinal axis. Preferably the cavity has a shape r
to the shape of the capsule. The cavity may have a circular cross-sectional shape and a first
diameter and the capsule may have a second diameter that is less than the first diameter. The
second diameter may be in a range from about 80% to about 99% of the first diameter. or the
second diameter may be in a range from about 90% to about 98% of the first diameter.
The article receptacle includes a acle second end that is configured to contain the
capsule and prevent the capsule from passing through the receptacle second end. The
receptacle second end may be d by a lateral wall integral with the body of the receptacle.
PCT/18201 7/053546
The receptacle second end may be defined by an end cap that is fixed to the body of the
receptacle. One or more air s may extend through the receptacle second end to allow air
to flow from the article cavity to the exterior of the article.
A membrane may seal the receptacle first end. The capsule may be placed into the
cavity of the receptacle through an open first end and then the membrane may seal the open
first end to retain the capsule within the cavity of the article. The membrane may form a
hermetic or airtight seal or barrier.
The membrane may be formed of a pierce-able material. The inhaler may include a
ng element that passes through the membrane and puncture the capsule within the
acle. The membrane may re-seal once the piercing element is retracted from the
membrane. Re-sealable membranes may include a septum-like element. lable
membranes may be formed of elastic material such as rubber, ne, metal foil co—laminated
with a polymer, or latex and the like. Alternatively, the membrane may not re-seal once the
piercing element is retracted from the membrane. The membranes may not re-seal and include
metal foil, for e.
An air inlet may extend h a side wall of the receptacle body and into the cavity.
The cavity may have a length in a range from about 15 mm to about 25 mm or from about 20
mm to about 24 mm. The cavity may have an inner diameter in a range from about 5 mm to
about 10 mm or from about 6 mm to about 8 mm. The cavity may have a length of about 20 mm
and an inner diameter of about 6.6 mm when containing a capsule size 3 flat. The cavity may
have a length of about 24 mm and an inner diameter of about 7.7 mm when ning a
capsule size 1 flat.
The air inlet may be closer to the receptacle first end than the receptacle second end.
The air inlet may be located within about 30%. or about 25%, or about 20%, or about 15%, or
about 10% of the total length from the receptacle first end. The air inlet may be located within
about 5 mm or within about 4 mm or within about 3 mm or within about 2 mm of the receptacle
first end. The air inlet may be located from about 1 mm to about 5 mm of the receptacle first end
or from about 2 mm to about 4 mm of the receptacle first end.
PCT/18201 7/053546
The air inlet may be off-set from the id longitudinal (central) axis of the acle
cavity or capsule contained within the cavity. The off-set air inlet s the capsule to rotate or
spin within the receptacle during inhalation by the consumer. The air inlet may be off-set from
the longitudinal (central) axis of the capsule or receptacle cavity by about 1 mm or about 2 mm
or about 3 mm or about 4 mm where the cavity may have an inner diameter of about 5 mm to
about 10 mm or from about 6 mm to about 8 mm. The one or more air inlets may have a
diameter from about 0.5 to about 1.5 mm or about 0.7 mm to about 0.9 mm. Preferably, the air
inlet directs air tangentially to the outer diameter of the capsule contained within the receptacle.
The article receptacle preferably has a circular cross-sectional shape extending (a length
1O distance) along its central axis and forming a cylindrical acle. Preferably the receptacle
defines a right ar cylinder with a radius and having a length extending along a central axis.
The air inlet may enter the receptacle tially to the cylindrical receptacle. Two or more air
inlets enter the acle cavity tangentially to the cylindrical receptacle. Preferably these air
inlets oppose each other and a first air inlet directs air tangentially to the cylindrical receptacle in
a first direction and the second air inlet directs air tangentially to the cylindrical receptacle in a
second direction that opposes or is in the opposite direction as the first direction. These
opposing air inlets may direct inhalation air at ng sides of the capsule contained within
the receptacle promoting the on of the capsule contained within the receptacle.
The capsule may be sealed within the article prior to ption or placement into an
inhaler. The article may be contained within a sealed or airtight ner or bag. The article
may include one or more peelable seal layers to cover the one or more air inlets or one or more
air outlets on the article. An air outlet seal layer may be disposed on the air outlet. This seal
layer may be configured to be punctured or be peelable to expose the air outlet. An air inlet seal
layer may be disposed on the air inlet. This seal layer may be configured to be punctured or be
peelable to expose the air inlet. The inhaler may e air inlet piercing element or an air
outlet piercing element that are configured to puncture one or both of these seal layers upon
insertion of the article into the r or upon activation of the inhaler.
The capsule is configured to rotate about its' longitudinal or central axis when air flows
through the article (from the air inlet through the receptacle to the air outlet). The capsule may
be formed of an airtight material that may be pierced or punctured by a piercing element that
PCT/18201 7/053546
may form part of the inhaler. The capsule may formed of a metallic or polymeric material that
serves to keep contaminates out of the capsule but may be pierced or punctured by a piercing
element prior to consumption of the nicotine particles within the capsule. Preferably, the capsule
is formed of a polymer material. The polymer al may be hydroxypropylmethylcellulose
(HPMC). Preferably, the capsule is a size 1 to size 4 or a size 3 capsule.
The e contains the solid ne particles (also referred to as “nicotine powder” or
cles comprising nicotine”) and optional flavour les. The capsule may contain a
predetermined amount of nicotine particles and optional flavour particles. The capsule may
contain enough nicotine particles to provide at least 2 inhalations or “puffs", or at least about 5
inhalations or “puffs", or at least about 10 inhalations or "puffs". Preferably. the capsule may
contain enough ne particles to provide from about 5 to 50 inhalations or ”puffs”, or from
about 10 to 30 inhalations or "puffs“. Each tion or "puff’ may deliver from about 0.1 mg to
about 3 mg of nicotine les to the lungs of the user or from about 0.2 mg to about 2 mg of
nicotine particles to the lungs of the user or about 1 mg of nicotine particles to the lungs of the
user.
The nicotine particles may have any useful concentration of nicotine based on the
particular formulation employed. The nicotine particles may have at least about 5%wt nicotine
up to about 30%wt, or from about 5%wt to about 25%wt. or from about 5%wt to about 20%wt,
or from about 5%wt to aboUt 15%wt, or from about 7%wt to about 13%wt, nicotine. Preferably,
about 50 to about 150 micrograms of nicotine is delivered to the lungs of the user with each
"puff”.
The capsule may hold or contain at least about 5 mg of ne particles or at least
about 10 mg of nicotine particles. Preferably, the capsule holds or contains less than about 900
mg of nicotine particles, or less than about 300 mg of nicotine particles. or less than 150 mg of
nicotine particles. The capsule may hold or contain from about 5 mg to about 300 mg of nicotine
particles or from about 10 mg to about 200 mg of nicotine particles.
When flavour particles are d or ed with the nicotine particles within the
capsule, the flavour les are present in an amount that provides the desired flavour to each
inhalation or "puff’ delivered to the user.
PCT/18201 7/053546
The nicotine les may have any useful size distribution for inhalation delivery
preferentially into the lungs of a user. The capsule may include other particles than the nicotine
les. The ne particles and the other particles form a powder system.
The capsule may hold or contain at least about 5 mg of a powder system or at least
about 10 mg of a powder system. Preferably, the capsule holds or contains less than about 900
mg of a powder system, or less than about 300 mg of a powder system, or less than 150 mg of
a powder system. The capsule may hold or contain from about 5 mg to about 300 mg of a
powder system or from about 10 mg to about 200 mg of a powder system.
The powder system may have at least about 40% or at least about 60%, or at least
about 80%, by weight of the powder system comprised in nicotine particles having a particle
size of about 10 etres or less, or 5 micrometers or less, or in a range from about 1
micrometer to about 3 micrometres.
ne in the powder system or nicotine particles is preferably a pharrnaceutically
acceptable free-base nicotine, or nicotine salt or nicotine salt hydrate. Useful nicotine salts or
nicotine salt hydrates include nicotine pyruvate, ne citrate, nicotine aspartate, nicotine
lactate, nicotine bitartrate, nicotine salicylate, nicotine fumarate, nicotine mono-pyruvate,
nicotine glutamate or nicotine hydrochloride, for example. The compound combining with
nicotine to form the salt or salt hydrate may be chosen based on its expected pharmacological
effect. For example: nicotine late may be stered for fever relief, as an anti-
inflammatory or painkiller; ne fumarate may be administered to treat multiple sclerosis; and
nicotine mono-pyruvate may be administered for treating chronic obstructive pulmonary disease
(COPD) or for weight loss.
The nicotine particles preferably e an amino acid. Preferably the amino acid is
leucine such as, ine. Providing an amino acid such as L-leucine with the les
comprising nicotine, may reduce adhesion forces of the particles comprising nicotine and may
reduce attraction between nicotine particles and thus reduce agglomeration of nicotine particles.
Similarly, adhesion forces to particles comprising flavour is also reduced thus
agglomeration of nicotine particles with flavour particles is also reduced. The powder system
PCT/18201 7/053546
described herein thus may be a free flowing material and possess a stable relative particle size
of each powder ent even when the nicotine particles and the flavour particles are
combined.
Preferably, the nicotine is a surface modified nicotine salt where the nicotine salt particle
is a coated or composite particle. A preferred coating or composite material is L-leucine. One
particularly useful nicotine particle is ne bitartrate with L-leucine.
The powder system may include flavour particles. The flavour les may have any
useful size distribution for inhalation delivery selectively into the mouth or buccal cavity of a
user.
The powder system may have at least about 40%, or at least about 60%, or at least
about 80%, by weight of the flavour of the powder system comprised in particles having a
particle size of about 20 micrometres or greater. The powder system may have at least about
40% or at least about 60%, or at least about 80%. by weight of the flavour of the powder system
comprised in particles having a particle size of about 50 micrometres or greater. The powder
system may have at least about 40% or at least about 60%, or at least about 80%, by weight of
the flavour of the powder system comprised in particles having a particle size in a range from
about 50 micrometer to about 150 etres.
Flavourants or flavours may be provided as a solid flavour (at room ature of about
22 degrees centigrade and one atmosphere pressure) and may include flavour formulations.
flavour-containing materials and flavour precursors. The ant may include one or more
l flavourants. one or more synthetic flavourants. or a combination of natural and synthetic
flavourants. Flavourants as described herein are organoleptic compounds, compositions, or
materials that are selected and utilized to alter or are intended to alter the taste or aroma
characteristics of the nicotine component during consumption or inhalation thereof.
Flavourants or flavours refer to a y of flavour materials of natural or synthetic origin.
They include single compounds and mixtures. Preferably the flavour or flavourant has flavour
properties that enhance the experience of the nicotine component during consumption.
Preferably. the flavour is chosen to e an experience similar to that ing from smoking
201 7/053546
a combustible smoking article. For example, the flavour or rant may enhance flavour
properties such as mouth fullness and complexity. xity is lly known as the overall
balance of the flavour being richer without dominating single sensory attributes. Mouth fullness
is described as perception of richness and volume in the mouth and throat of the consumer.
Suitable flavours include, but are not limited to, any natural or synthetic flavour, such as
tobacco, smoke, l, mint (such as peppermint and speannint), ate, licorice, citrus
and other fruit flavours, gamma octalactone, vanillin, ethyl vanillin, breath freshener flavours,
spice flavours such as on, methyl salicylate, ol, bergamot oil, geranium oil, lemon
oil, and ginger oil, and the like.
Other suitable flavours may include flavour compounds selected from the group
consisting of an acid, an alcohol, an ester, an aldehyde, a ketone, a pyrazine, combinations or
blends thereof and the like. Suitable flavour compounds may be selected, for example, from the
group consisting of phenylacetic acid, solanone, megastigmatrienone, 2-heptanone,
benzylalcohol, cishexenyl acetate, valeric acid, valeric aldehyde, ester, terpene,
sesquiterpene, nootkatone. maltol, damascenone, pyrazine, lactone, anethole, iso-s valeric
acid, combinations f, and the like.
Further specific examples of flavours may be found in the current literature, and are well—
known to the person skilled in the art of flavouring, i.e. of imparting an odor or taste to a product.
The flavourant may be a high potency flavourant, and may be used and detected at
levels that would result in less than 200 parts per million in inhalation air flow. Examples of
such flavourants are key tobacco aroma compounds such as beta-damascenone, 2-ethyl-3,5-
dimethylpyrazine, phenylacetaldehyde, guaiacol, and furaneol. Other flavourants may only be
sensed by humans at higher concentration levels. These ants, which are referred to
herein as the lower potency flavourants, are typically used at levels that results in orders of
magnitude higher amounts of flavourant released into the inhalation air. le lower potency
ants include, but are not limited to, natural or synthetic menthol, mint, Spearmint,
coffee, tea, spices (such as on, clove and ginger), cocoa, vanilla, fruit flavours,
chocolate, eucalyptus, geranium, eugenol and linalool.
PCT/18201 7/053546
The particles sing flavour may include a compound to reduce adhesion forces or
surface energy and resulting agglomeration. The flavour particle may be surface modified with
an on reducing compound to form a coated r particle. One preferred adhesion
reducing compound is magnesium te. Providing an adhesion reducing compound such as
magnesium stearate with the flavour particle. especially g the flavour particle, s
adhesion forces of the particles comprising flavour and may reduce attraction between flavour
particles and thus reduce agglomeration of flavour particles. Thus agglomeration of flavour
particles with nicotine particles is also reduced. The powder system described herein thus may
possess a stable relative particle size of the particles sing nicotine and the particles
comprising flavour even when the nicotine les and the flavour particles are combined. The
powder system preferably is free flowing.
Conventional formulations for dry powder inhalation typically contain carrier particles that
serve to increase the fluidization of the active particles since the active particles may be too
small to be influenced by simple w though the inhaler. The powder system may comprise
r les. These carrier particles may be a saccharide such as lactose or mannitol that
have a particle size greater than about 50 micrometres. The carrier particles may be utilized to
improve dose uniformity by acting as a diluent or bulking agent in a formulation.
The powder system utilized with the nicotine powder delivery system described herein
may be carrier-free or substantially free of a saccharide such as lactose or mannitol. Being
carrier-free or substantially free of a saccharide such as lactose or ol may allow the
nicotine and to be inhaled and delivered to the user's lungs at inhalation or airflow rates that are
similar to typical smoking regime inhalation or airflow rates. In addition, since the ne is
carrier-free or substantially free of a saccharide such as lactose or mannitol, the airflow path of
the inhaler may have simple geometry or a simple ration.
The nicotine particles and a flavour may be combined in a single capsule. As described
above, the ne particles and a flavour may each have d adhesion forces that result in
a stable particle formulation where the particle size of each component does not substantially
change when combined. Alternatively, the powder system includes nicotine particles contained
within a single capsule and the flavour particles contained within a second capsule.
PCT/18201 7/053546
The nicotine particles and flavour particles may be combined in any useful relative
amount so that the flavour particles are detected by the user when consumed with the nicotine
particles. Preferably the nicotine particles and a flavour les form at least about 90%wt or at
least about 95%wt or at least about 99%wt or 100%wt of the total weight of the powder system.
The nicotine particle delivery consumable (article) and inhaler are less complex and
have a simplified storage and airflow path as compared to conventional dry powder inhalers.
Advantageously, rotation of the e within the inhaler aerosolizes the nicotine particles or
powder system and may assist in maintaining a free flowing powder. Thus, the inhaler does not
e the typical high inhalation rates of conventional inhalers to deliver the nicotine particles
described above deep into the lungs.
The inhaler may use a flow rate of less than about 5 Umin or less than about 3 L/min or
less than about 2 Umin or about 1.6 L/min. Preferably, the flow rate is in a range from about 1
L/min to about 3 Umin or from about 1.5 Umin to about 2.5 L/min. Preferably, the inhalation
rate or flow rate is similar to that of Health Canada smoking , that is, about 1.6 Umin.
The inhaler may be used by a consumer like smoking a conventional cigarette or vaping
an electronic cigarette. Such smoking or vaping is characterized by two steps: a first step
during which a small volume containing the full amount of ne desired by the consumer is
drawn into the mouth cavity, followed by a second step during which this small volume
comprising the aerosol comprising the desired amount of ne is further diluted by fresh air
and drawn deeper into the lungs. Both steps are controlled by the consumer. During the first
tion step the consumer may determine the amount of nicotine to be inhaled. During the
second step, the consumer may determine the volume for diluting the first volume to be drawn
deeper into the lungs, maximizing the tration of active agent delivered to the aiwvay
epithelial surface. This g mechanism is sometimes called "puff»inhale-exhale".
A piercing element, such as a metal or rigid needle, may form a single aperture h
the capsule received in the acle. The piercing element may pass through the membrane
sealing the receptacle first end.
PCT/18201 7/053546
All ific and technical terms used herein have meanings commonly used in the art
unless ise specified. The definitions provided herein are to facilitate understanding of
certain terms used frequently herein.
The terms eam” and “downstream" refer to relative positions of elements of the
inhaler described in on to the direction of inhalation air flow as it is drawn through the body
of the inhaler from a distal end portion to the mouthpiece portion.
As used herein, the singular forms “a
, an", and "the" encompass embodiments having
plural referents, unless the content clearly dictates othen/vise.
As used herein, “or“ is generally employed in its sense including “and/or” unless the
content clearly dictates ise. The term “and/or“ means one or all of the listed elements or a
combination of any two or more of the listed elements.
As used herein, “have”, “havingI) u' u
, include”, “includingn , comprise", "comprising” or the
like are used in their open ended sense, and generally mean “including, but not limited to”. It
will be understood that “consisting essentially of", “consisting of“. and the like are subsumed in
"comprising,” and the like.
The words rred” and “preferably” refer to embodiments of the invention that may
afford certain benefits, under certain circumstances. However, other embodiments may also be
preferred. under the same or other circumstances. Furthermore, the recitation of one or more
preferred embodiments does not imply that other embodiments are not useful, and is not
intended to e other embodiments from the scope of the disclosure, including the claims.
FlG.s 1-2 are perspective schematic diagrams of illustrative nicotine particle delivery
ables or articles 100. is a cross-sectional tic diagram of an illustrative
nicotine particle delivery consumable or article 100. is a sectional schematic
diagram of an illustrative inhaler 200 with a modular article or nicotine particle delivery
consumable 100 disposed n.
The schematic drawings are not necessarily to scale and are presented for purposes of
illustration and not tion. The drawings depict one or more aspects described in this
WO 07887 PCT/l82017/053546
disclosure. r. it will be tood that other s not depicted in the drawing fall
within the scope and spirit of this disclosure.
Referring now to and the rative nicotine particle delivery consumable
100 or article and the cross-section of The nicotine particle delivery consumable or
article 100 includes a receptacle 110 having a body or sidewall 112 extending from a receptacle
first end 111 to an opposing receptacle second end 113 and defining a cavity 116. A capsule
120 is disposed within the cavity 116. The e 120 contains particles comprising nicotine.
illustrates the e 120 exploded away from the receptacle 110. The nicotine particle
delivery consumable or article 100 may be formed by inserting the capsule 120 into the
1O receptacle 110 and applying the membrane 115 on the receptacle first end 111 to seal the
acle first end 111 and retain the capsule 120 within the receptacle 110.
The receptacle 110 includes a lateral wall 114 fixed to or integral with the receptacle
body or sidewall 112 and an air outlet 118 extending through the lateral wall 114 and into the
cavity 116. A membrane 115 seals the receptacle first end 111. An air inlet 117 extends through
the ll 112 or body 112 and into the cavity 116. The air inlet 117 is proximate the
receptacle first end 111 or closer to the receptacle first end 111 than the receptacle second end
113. The cavity 116 has a length value L and a diameter value D. The air inlet 117 is proximate
the receptacle proximal end 111 a distance L1.
The nicotine particle delivery consumable or article 100 may be a modular or a
replaceable component of a re-usable inhaler 200. is a cross-sectional schematic
diagram of an illustrative inhaler 200 with a modular illustrative ne particle delivery
consumable or article 100 disposed therein.
The illustrative inhaler 200 es a mouthpiece portion 210 and a detachable distal
portion 220. The mouthpiece portion 210 includes a receptacle cavity 212 in air flow
communication with a mouthpiece air l 214. The mouthpiece portion 210 includes one or
more iece air outlets 216 that mate or align with the air outlet 118 of the nicotine particle
delivery consumable or article 100. One or more Inlet air flow channels mate with the one or
more air inlets 117 of the nicotine particle delivery consumable or article 100.
PCT/lBZOl7/053546
The acle cavity 212 is configured to mate with the nicotine particle delivery
consumable or article 100. The detachable distal portion 220 may be removed from the
mouthpiece portion 210 to expose the receptacle cavity 212 to replace the modular and used or
depleted nicotine particle delivery consumable or article 100 with an un-used or full particle
delivery consumable or article 100.
The distal portion 220 es a piercing element 225 that may be a plunger type
element with a resilient element 228 such as a spring element. The piercing element 225
includes a piercing needle 221. Depressing the piercing element 225 allows the piercing needle
221 to pass through the membrane 115 and puncture the capsule 120. Air flow ment
through the nicotine particle delivery consumable or e 100 causes the capsule 120 to rotate
about its longitudinal axis. Nicotine and optional flavour particles are then entrained into the air
flow through the r article 200.
Once the nicotine le delivery consumable or article 100 is consumed, the depleted
nicotine particle delivery consumable or article 100 may then be removed from the receptacle
cavity 212 and replaced with a fresh nicotine particle delivery able or article 100. One or
more seal layers (not shown) may be peeled away or punctured by elements of the receptacle
cavity 212 to e air flow through the nicotine particle delivery consumable or article 100.
rpaaiéds isfoSié'cfi'é‘: c'Eiifs'EAiubf PCT/'3 2017/0” 5461322>i78§a§2618
REPLACEMENT SHEET
FTR1774/WO
MRG 44201200201
.15.
Claims (5)
1. An article for use In a ne inhaler. comprising: a acle comprising: a body comprising a sidewall extending from a receptacle first end to an ng receptacle second end and defining a cavity; a -able membrane sealing the acle first end; an air outlet extending through the receptacle second end into the cavity: an air inlet extending through the body ll and into the . the air inlet being closer to the receptacle first end than the receptacle second end; and a pierce-able capsule disposed within the cavity, the capsule containing particles comprising nicotine sized for inhalation delivery into the lungs of a user.
2. The article according to claim 1. wherein the -able membrane is an elastic material that is configured to reseal alter being punctured.
3. The article according to claim 1. wherein the pierce-able membrane is a metal foil.
4. The article according to any one of the preceding claims. wherein the air inlet is off- set from a centroid longitudinal axis of the cavity. and air flowing from the air inlet to the air outlet causes the capsule to rotate about the capsule longitudinal axis.
5. The article according to any one of the preceding claims. wherein the cavity has a circular cross-sectional shape and the air inlet ls tangential to the cavity. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16178336.0 | 2016-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ747468A true NZ747468A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11273268B2 (en) | Nicotine inhaler system | |
US11471622B2 (en) | Inhaler with swirl end plug | |
US10960152B2 (en) | Nicotine particle capsule | |
US10945460B2 (en) | Nicotine particle delivery consumable | |
CA3008211A1 (en) | Nicotine powder delivery system | |
US11260184B2 (en) | Inhaler with sized cavity | |
US20210113787A1 (en) | Dry powder inhaler | |
EP3950029A1 (en) | Piercing accessory for inhaler article and system | |
EP3700376A1 (en) | Inhaler with boundary element | |
NZ747468A (en) | Nicotine particle delivery consumable | |
NZ747467A (en) | Nicotine inhaler system |